Enavate Sciences GP LLC Makes New $36.94 Million Investment in Immunome, Inc. (NASDAQ:IMNM)

Enavate Sciences GP LLC purchased a new stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 3,478,261 shares of the company's stock, valued at approximately $36,939,000. Immunome accounts for 26.5% of Enavate Sciences GP LLC's investment portfolio, making the stock its 2nd largest holding. Enavate Sciences GP LLC owned about 4.36% of Immunome at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of IMNM. BNP Paribas Financial Markets bought a new stake in Immunome during the 4th quarter valued at approximately $70,000. KLP Kapitalforvaltning AS bought a new stake in shares of Immunome in the 4th quarter worth approximately $75,000. AlphaQuest LLC boosted its position in shares of Immunome by 786,700.0% in the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock worth $84,000 after purchasing an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after purchasing an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in shares of Immunome in the 4th quarter worth approximately $95,000. Hedge funds and other institutional investors own 44.58% of the company's stock.

Immunome Trading Down 0.3%

IMNM stock traded down $0.02 during midday trading on Wednesday, hitting $7.89. The company's stock had a trading volume of 631,761 shares, compared to its average volume of 917,702. The company has a market cap of $686.52 million, a PE ratio of -0.97 and a beta of 2.00. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $16.81. The firm's 50-day moving average is $7.71 and its 200-day moving average is $9.90.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.14. The business had revenue of $2.93 million during the quarter, compared to analyst estimates of $0.46 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. Analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Guggenheim dropped their price target on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, March 20th. Lifesci Capital assumed coverage on Immunome in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price objective on the stock. Stephens reaffirmed an "overweight" rating and issued a $30.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Wedbush reaffirmed an "outperform" rating and issued a $21.00 price objective (down from $33.00) on shares of Immunome in a research report on Tuesday. Finally, Lake Street Capital assumed coverage on Immunome in a research report on Wednesday, April 2nd. They issued a "buy" rating and a $23.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Immunome presently has an average rating of "Buy" and an average price target of $23.33.

Insider Buying and Selling at Immunome

In related news, CTO Philip Tsai acquired 12,300 shares of Immunome stock in a transaction dated Monday, March 24th. The stock was purchased at an average cost of $8.42 per share, for a total transaction of $103,566.00. Following the purchase, the chief technology officer now directly owns 33,300 shares of the company's stock, valued at approximately $280,386. This trade represents a 58.57% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jean Jacques Bienaime acquired 7,000 shares of Immunome stock in a transaction dated Monday, March 24th. The stock was bought at an average price of $8.21 per share, with a total value of $57,470.00. Following the completion of the purchase, the director now directly owns 23,615 shares in the company, valued at $193,879.15. This represents a 42.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 156,400 shares of company stock worth $1,160,495. Insiders own 8.60% of the company's stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.